United States - English - NLM (National Library of Medicine)

stat rx usa - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), benzyl alcohol (unii: lkg8494wbh) (benzyl alcohol - unii:lkg8494wbh) - ciprofloxacin hydrochloride 2 mg in 1 ml - cipro® hc otic is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of pseudomonas aeruginosa, staphylococcus aureus, and proteus mirabilis. cipro® hc otic is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. this nonsterile product should not be used if the tympanic membrane is perforated. use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see   warnings and precautions (5.1 )] . the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids,

United States - English - NLM (National Library of Medicine)

stat rx usa llc - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - bacitracin zinc 500 [usp'u] in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin b sulfate. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 750 mg

United States - English - NLM (National Library of Medicine)

stat rx usa llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg

United States - English - NLM (National Library of Medicine)

stat rx usa llc - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel bisulfate 75 mg - plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: - recent mi, recent stroke or established peripheral arterial disease for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not), and other vascular death. - acute coronary syndrome - for patients with non-st-segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg, plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, mi, or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-segment elevation acute myocardial infarcti

United States - English - NLM (National Library of Medicine)

stat rx usa llc - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin 3 mg in 1 ml - ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: otitis externa in adults and pediatric patients, 6 months and older, due to escherichia coli, pseudomonas aeruginosa, and staphylococcus aereus . chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes due to proteus mirabilis, pseudomonas aeruginosa and staphylococcus aureus . acute otitis media in pediatric patients one year and older with tympanostomy tubes due to haemophilus influenzae, moraxella catarrhalis, pseudomonas aeruginosa, staphylococcus aureus, and streptococcus pneumoniae . ofloxacin otic solution 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 80 mg - oxycontin tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. oxycontin is not intended for use as a prn analgesic. physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the world health organization, the agency for healthcare research and quality (formerly known as the agency for healthcare policy and research), the federation of state medical boards model guidelines, or the american pain society. oxycontin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. oxycontin is only indicated for

United States - English - NLM (National Library of Medicine)

stat rx usa llc - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone 17-monopropionate - unii:5bga9fd55h) - beclomethasone 17-monopropionate 40 ug - qvar is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. qvar is also indicated for asthma patients who require systemic corticosteroid administration, where adding qvar may reduce or eliminate the need for the systemic corticosteroids. beclomethasone dipropionate is not indicated for the relief of acute bronchospasm. qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. hypersensitivity to any of the ingredients of this preparation contraindicates its use.

United States - English - NLM (National Library of Medicine)

stat rx usa - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets, usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for decreasing the risk